The pandemic of coronavirus disease 2019 (COVID‐19), caused by the severe acute
respiratory syndrome coronavirus 2 (SARS‐CoV‐2), has caused an unprecedented global …

Outcomes for patients with hematologic malignancy infected with COVID-19 have not been
aggregated. The objective of this study was to perform a systematic review and meta …

Background Patients with coronavirus disease 2019 (COVID-19) who have underlying
malignancy have a higher mortality rate compared with those without cancer, although the …

Published series on COVID-19 support the notion that patients with cancer are a particularly
vulnerable population. There is a confluence of risk factors between cancer and COVID-19 …

Background This study applies an umbrella review approach to summarise the global
evidence on the risk of severe COVID-19 outcomes in patients with pre-existing health …

Importance SARS-CoV-2 infection has been associated with more severe disease and
death in patients with cancer. However, the implications of certain tumor types, treatments …

Given the immune system's importance for cancer surveillance and treatment, we have
investigated how it may be affected by SARS-CoV-2 infection of cancer patients. Across …

Importance Large cohorts of patients with active cancers and COVID-19 infection are
needed to provide evidence of the association of recent cancer treatment and cancer type …

Background Using an updated dataset with more patients and extended follow-up, we
further established cancer patient characteristics associated with COVID-19 death. Methods …

Background A systematic review and meta-analysis was performed to estimate mortality in
adult patients with solid or hematological malignancies and SARS-CoV-2 infection. Methods …